Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial
Published . Updated .
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite DirectionsAlnylam Pharmaceuticals (NASDAQ:ALNY) outlined its strategy for advancing zilebesiran, an investigational RNA interference, or RNAi, therapy designed to provide sustained blood-pressure control with tw
Directly affected
Indirectly affected
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GEHC GE HEALTHCARE TECHNOLOGIES I
GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite DirectionsAlnylam Pharmaceuticals (NASDAQ:ALNY) outlined its strategy for advancing zilebesiran, an investigational RNA interference, or RNAi, therapy designed to provide…
Source: Nasdaq Markets
Acadia Healthcare (ACHC) since this story, compared with the market
Since the first closing price after “Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial,” Acadia Healthcare (ACHC) is +2.70%. The S&P 500 fund (SPY) is -0.88% over the same days, a +3.59% difference versus the market.
Disclosure records for Acadia Healthcare (ACHC) within two months of 21 Sep 2026
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 8 days after publication, inside 30 days. The filing is listed beside the story “Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 10 days before publication, inside 30 days. The filing is listed beside the story “Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 49 days before publication, inside 60 days. The filing is listed beside the story “Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 53 days before publication, inside 60 days. The filing is listed beside the story “Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 53 days before publication, inside 60 days. The filing is listed beside the story “Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 60 days before publication, inside 60 days. The filing is listed beside the story “Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Acadia Healthcare (ACHC)
Companies tied to this story
- ACHC Acadia Healthcare
For “Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
In “Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence in the 21 Sep 2026 story “Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial.” Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
In “Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
In “Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial,” Davita (DVA) is linked, with no stored direction, medium confidence. Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEHC GE HealthCare Technologies
GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence in the 21 Sep 2026 story “Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial.” Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Acadia Healthcare (ACHC)
Acadia Healthcare (ACHC) is the company in “Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial,” the 21 Sep 2026 this story story.
For Acadia Healthcare (ACHC), the reason on file says GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
A second company, Ascendis Pharma A/S (ASND), is listed for a different reason: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
The price range for Acadia Healthcare (ACHC), and the dates in the story
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. ATYR traded between 0.17 and 0.41 across 20 sessions. The latest close on file is 0.17.
A simple score for Acadia Healthcare (ACHC)
46 out of 100
“Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.